Mucosal effects of tenofovir 1% gel.

Détails

ID Serval
serval:BIB_66FFD7CCC21C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Mucosal effects of tenofovir 1% gel.
Périodique
eLife
Auteur⸱e⸱s
Hladik F., Burgener A., Ballweber L., Gottardo R., Vojtech L., Fourati S., Dai J.Y., Cameron M.J., Strobl J., Hughes S.M., Hoesley C., Andrew P., Johnson S., Piper J., Friend D.R., Ball T.B., Cranston R.D., Mayer K.H., McElrath M.J., McGowan I.
ISSN
2050-084X (Electronic)
ISSN-L
2050-084X
Statut éditorial
Publié
Date de publication
03/02/2015
Peer-reviewed
Oui
Volume
4
Langue
anglais
Notes
Publication types: Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
Publication Status: epublish
Résumé
Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission. Because this is a new prevention strategy, we broadly assessed its effects on the mucosa. In MTN-007, a phase-1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies (15 subjects/arm). We also treated primary vaginal epithelial cells from four healthy women with tenofovir in vitro. After seven days of administration, tenofovir 1% gel had broad-ranging effects on the rectal mucosa, which were more pronounced than, but different from, those of the detergent nonoxynol-9. Tenofovir suppressed anti-inflammatory mediators, increased T cell densities, caused mitochondrial dysfunction, altered regulatory pathways of cell differentiation and survival, and stimulated epithelial cell proliferation. The breadth of mucosal changes induced by tenofovir indicates that its safety over longer-term topical use should be carefully monitored.
Mots-clé
Double-Blind Method, Female, Gels, Gene Expression/drug effects, Humans, Male, Mitochondria/drug effects, Mucous Membrane/drug effects, Mucous Membrane/metabolism, Proteomics, Rectum/drug effects, Rectum/metabolism, Reverse Transcriptase Inhibitors/administration & dosage, Reverse Transcriptase Inhibitors/adverse effects, Tenofovir/administration & dosage, Tenofovir/adverse effects, Vagina/drug effects, Vagina/metabolism, HIV/AIDS, human, human biology, infectious disease, medicine, microbicides, microbiology, mucosa, prevention, side effects
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/02/2022 11:45
Dernière modification de la notice
23/03/2024 7:24
Données d'usage